Clinical Scorecard: Response to Goldman and Martin on the External Clinical Validation of the RECOVER Research Index
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: Response to Goldman and Martin on the External Clinical Validation of the RECOVER Research Index
Key Mechanisms
Mechanisms or clinical associations described in the source article.
Target Population
Population described in the source article.
Care Setting
Specialty referral cohort evaluated for suspected Long COVID; the study was not designed to assess performance in the general population.
Key Highlights
The study assessed external clinical validation of the RECOVER PASC score in a rigorously phenotyped specialty referral cohort, not performance in the general population.
Clinical diagnoses applied the 2024 NASEM consensus definition as the reference standard because Long COVID lacks a biological gold standard.
The authors report high specificity versus recovered SARS-CoV-2 controls.
Positive and negative predictive values were descriptive of the study cohort and should not be extrapolated to populations with different disease prevalence.
The authors identify community, primary care, broader clinical phenotype, and symptom-overlap comparator studies as complementary areas for future evaluation.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
The authors state that subsequent investigations should evaluate community-based populations, primary care settings, and more expansive clinical phenotypes of Long COVID.
Future studies comparing Long COVID with conditions that share symptoms could provide complementary data on differential diagnostic performance.
Risks
Patient & Prescribing Data
No treatment or prescribing data are reported. The article reports diagnostic performance, including high specificity versus recovered controls.
Clinical Best Practices
Interpret diagnostic performance in light of the cohort’s referral setting, enrollment criteria, and comparator group.
Do not treat cohort-specific predictive values as estimates for broader clinical or community populations.
Use complementary studies across community, primary care, and specialty settings, including comparisons with conditions that share symptoms, to characterize score performance.
